Table 1 from Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

Key Points

• The analysis population includes patients with advanced breast cancer receiving no prior systemic therapy.
• Key characteristics such as demographic data and baseline disease status were documented for targeted therapies.
• Median ages and disease stages were compared, supporting insights into treatment efficacy.
• Reflects findings on the combination therapy of gedatolisib, palbociclib, and letrozole in clinical practice.